Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

Item

http://www.wikidata.org/entity/Q39006105

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@en

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@nl

type

Item

label

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@en

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@nl

prefLabel

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@en

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@nl

P1476

Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.

@en

P2093

Charles F Shaefer

http://www.w3.org/2001/XMLSchema#string

Eugene E Wright

http://www.w3.org/2001/XMLSchema#string

John E Anderson

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Association of Cardiometabolic Multimorbidity With Mortality

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

10-year follow-up of intensive glucose control in type 2 diabetes

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

P2888

s13300-016-0211-x

P304

33-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13300-016-0211-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27837465

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

5306110

http://www.w3.org/2001/XMLSchema#string